Qian Chu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1529466/publications.pdf

Version: 2024-02-01

116 papers	4,919 citations	109321 35 h-index	110387 64 g-index
124 all docs	124 docs citations	124 times ranked	7333 citing authors

#	Article	IF	Citations
1	Impact of marital status on survival in patients with stage 1A NSCLC. Aging, 2022, 14, 770-779.	3.1	6
2	SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway. Journal of Cancer, 2022, 13, 527-540.	2.5	7
3	Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Translational Lung Cancer Research, 2022, 11, 173-187.	2.8	6
4	Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 295-306.	2.8	16
5	NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance. Frontiers in Oncology, 2022, 12, 864666.	2.8	28
6	Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduction and Targeted Therapy, 2022, 7, 95.	17.1	229
7	The roles of CC chemokines in response to radiation. Radiation Oncology, 2022, 17, 63.	2.7	21
8	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model. Frontiers in Immunology, 2022, 13, 829634.	4.8	7
9	Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	4.0	3
10	Abstract CT513: Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China. Cancer Research, 2022, 82, CT513-CT513.	0.9	7
11	Lower lobe origin is related to unfavorable outcomes in patients with stage Iâ€“III lung cancer treated with radical chemoradiotherapy. Tumori, 2021, 107, 400-406.	1.1	1
12	Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVIDâ€19: A multicenter study. Cancer, 2021, 127, 437-448.	4.1	17
13	Repurposed Tocilizumab in Patients with Severe COVID-19. Journal of Immunology, 2021, 206, 599-606.	0.8	17
14	Immune signature-based risk stratification and prediction of immune checkpoint inhibitorâ€™s efficacy for lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1705-1719.	4.2	96
15	Prognostic significance of KRT19 in Lung Squamous Cancer. Journal of Cancer, 2021, 12, 1240-1248.	2.5	12
16	Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey. Frontiers in Pharmacology, 2021, 12, 583126.	3.5	2
17	Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 625578.	2.8	8
18	Lymphocyte may be a reference index of the outcome of cancer patients with COVID-19. Aging, 2021, 13, 7733-7744.	3.1	4

#	Article	IF	Citations
19	Correlation of [18F]florbetaben textural features and age of onset of Alzheimerâ€™s disease: a principal components analysis approach. EJNMMI Research, 2021, 11, 40.	2.5	3
20	Individualized model for predicting COVIDâ€19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Science, 2021, 112, 2522-2532.	3.9	6
21	A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy. Translational Lung Cancer Research, 2021, 10, 2163-2171.	2.8	6
22	International consensus on severe lung cancerâ€”the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	2.8	6
23	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. Frontiers in Immunology, 2021, 12, 693609.	4.8	21
24	Salvage surgery following downstaging of advanced nonâ€small cell lung cancer by targeted therapy. Thoracic Cancer, 2021, 12, 2161-2169.	1.9	6
25	Anti-inflammatory and Antioxidant Activity of Peptides From Ethanol-Soluble Hydrolysates of Sturgeon (Acipenser schrenckii) Cartilage. Frontiers in Nutrition, 2021, 8, 689648.	3.7	15
26	Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. Annals of Translational Medicine, 2021, 9, 1014-1014.	1.7	4
27	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. International Journal of Biochemistry and Cell Biology, 2021, 136, 106002.	2.8	6
28	Epidemiological trends of womenâ€™s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomarker Research, 2021, 9, 55.	6.8	67
29	Characteristics of immune and inflammatory responses among different age groups of pediatric patients with COVID-19 in China. World Journal of Pediatrics, 2021, 17, 375-384.	1.8	10
30	Sintilimab, stereotactic body radiotherapy and granulocyteâ€“macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiation Oncology, 2021, 16, 177.	2.7	14
31	Combine and conquer: manganese synergizing anti-TGF-Î²/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Journal of Hematology and Oncology, 2021, 14, 146.	17.0	68
32	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	2.8	12
33	GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 2336-2345.	4.4	27
34	Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer. Communications Biology, 2021, 4, 131.	4.4	12
35	A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	4
36	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Lung Cancer, 2020, 139, 118-123.	2.0	33

#	Article	IF	Citations
37	Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. Immunotherapy, 2020, 12, 1195-1207.	2.0	2
38	Clinical outcomes of coronavirus disease 2019 (COVIDâ€19) in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Communications, 2020, 40, 374-379.	9.2	29
39	Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the Peopleâ€™s Republic of China. JTO Clinical and Research Reports, 2020, 1, 100053.	1.1	11
40	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nature Communications, 2020, 11, 6119.	12.8	53
41	Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation. Frontiers in Oncology, 2020, 10, 1288.	2.8	29
42	Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients. Current Medical Science, 2020, 40, 618-624.	1.8	51
43	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine, 2020, 18, 232.	5.5	15
44	CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opinion on Investigational Drugs, 2020, 29, 1295-1308.	4.1	17
45	Discussion of Advance Care Planning on end of life decisions with lung cancer patients in Wuhan China: Attitude, Timing, and Future Directions. Internal Medicine Journal, 2020, , .	0.8	5
46	Prevention, susceptibility, and clinical features of coronavirus disease 2019 in postoperative patients. Asian Journal of Surgery, 2020, 43, 1209-1211.	0.4	0
47	PDPN is a prognostic biomarker and correlated with immune infiltrating in gastric cancer. Medicine (United States), 2020, 99, e19957.	1.0	17
48	NRF2-Driven KEAP1 Transcription in Human Lung Cancer. Molecular Cancer Research, 2020, 18, 1465-1476.	3.4	9
49	NEMA-2008 and In-Vivo Animal and Plant Imaging Performance of the Large FOV Preclinical Digital PET/CT System Discoverist 180. IEEE Transactions on Radiation and Plasma Medical Sciences, 2020, 4, 622-629.	3.7	15
50	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. Journal of Hematology and Oncology, 2020, 13, 72.	17.0	123
51	Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. BioMed Research International, 2020, 2020, 1-15.	1.9	26
52	Improving tumor hypoxia and radiotherapy resistance via in situ nitric oxide release strategy. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 150, 96-107.	4.3	17
53	The Role of NLRP3 Inflammasome in Radiation-Induced Cardiovascular Injury. Frontiers in Cell and Developmental Biology, 2020, 8, 140.	3.7	23
54	Coronavirus Disease 2019 in the Perioperative Period of Lung Resection: A Brief Report From a Single Thoracic Surgery Department in Wuhan, Peopleâ€™s Republic of China. Journal of Thoracic Oncology, 2020, 15, 1065-1072.	1.1	93

#	Article	IF	Citations
55	Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	1.0	3
56	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 355.	8.6	47
57	Di-n-butyl phthalate degrading endophytic bacteriumBacillus amyloliquefaciens subsp.strain JR20 isolated from garlic chive and its colonization in a leafy vegetable. Journal of Environmental Science and Health - Part B Pesticides, Food Contaminants, and Agricultural Wastes, 2019, 54, 693-701.	1.5	7
58	Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell Death and Disease, 2019, 10, 777.	6.3	26
59	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Experimental Hematology and Oncology, 2019, 8, 26.	5.0	58
60	Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (<scp>ALK</scp>)â€rearranged nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3382-3390.	3.9	26
61	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integrative Cancer Therapies, 2019, 18, 153473541987635.	2.0	38
62	Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of Hematology and Oncology, 2019, 12, 98.	17.0	92
63	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy, 2019, 11, 429-441.	2.0	44
64	Gut microbiome and cancer immunotherapy. Cancer Letters, 2019, 447, 41-47.	7.2	159
65	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Molecular Cancer, 2019, 18, 60.	19.2	361
66	Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. Journal of Hematology and Oncology, 2019, 12, 35.	17.0	220
67	Advances and perspectives of PARP inhibitors. Experimental Hematology and Oncology, 2019, 8, 29.	5.0	81
68	Blocking TGF-Î² Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor . OncoTargets and Therapy, 2019, Volume 12, 9527-9538.	2.0	93
69	Were the more examined lymph nodes the better for stage IA NSCLC patients? A Population Study of the US SEER Database. Annals of Oncology, 2019, 30, vi108.	1.2	0
70	Immune pressures drive the promoter hypermethylation of neoantigen genes. Experimental Hematology and Oncology, 2019, 8, 32.	5.0	11
71	EGFRâ€TKIs plus local therapy demonstrated survival benefit than EGFRâ€TKIs alone in EGFRâ€mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. International Journal of Cancer, 2019, 144, 2605-2612.	5.1	30
72	Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients. Cancer Biology and Medicine, 2019, 16, 556-564.	3.0	36

#	Article	IF	Citations
73	Estrogen receptor Î²1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Oncology Reports, 2018, 39, 1313-1321.	2.6	12
74	Effectiveness of comprehensive social support interventions among elderly patients with tuberculosis in communities in China: a community-based trial. Journal of Epidemiology and Community Health, 2018, 72, 369-375.	3.7	39
75	Gut microbiome modulates efficacy of immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 47.	17.0	138
76	Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer and Metastasis Reviews, 2018, 37, 733-748.	5.9	158
77	The role of gut microbiota in immune checkpoint inhibitor therapy. Hepatobiliary Surgery and Nutrition, 2018, 7, 481-483.	1.5	16
78	The role of neoantigen in immune checkpoint blockade therapy. Experimental Hematology and Oncology, 2018, 7, 28.	5.0	99
79	Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Experimental Hematology and Oncology, 2018, 7, 30.	5.0	119
80	EGFR-TKIs resistance via EGFR-independent signaling pathways. Molecular Cancer, 2018, 17, 53.	19.2	223
81	Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation. Cellular Physiology and Biochemistry, 2017, 44, 778-791.	1.6	21
82	Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Oncotarget, 2017, 8, 62330-62338.	1.8	5
83	Identification of Risk Factors of Multidrug-Resistant Tuberculosis by using Classification Tree Method. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1720-1725.	1.4	2
84	A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. International Journal of Nanomedicine, 2016, 11, 2119.	6.7	17
85	Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres. Brain Pathology, 2016, 26, 713-723.	4.1	42
86	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 83.	17.0	45
87	The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Letters, 2016, 377, 55-64.	7.2	50
88	Emerging roles of Nrf2 signal in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 14.	17.0	50
89	Crosstalk between ATF4 and MTA1/HDAC1 promotes osteosarcoma progression. Oncotarget, 2016, 7, 7329-7342.	1.8	30
90	D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery. International Journal of Nanomedicine, 2015, 10, 5219.	6.7	21

#	Article	IF	Citations
91	Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35, 752-758.	1.0	14
92	Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Scientific Reports, 2015, 5, 10338.	3.3	96
93	Notch signaling: An emerging therapeutic target for cancer treatment. Cancer Letters, 2015, 369, 20-27.	7.2	336
94	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Letters, 2015, 369, 97-102.	7.2	82
95	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS ONE, 2015, 10, e0131689.	2.5	75
96	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget, 2015, 6, 5877-5888.	1.8	40
97	Abstract 1074: Epigenetic silencing of DACH1 in triple negative breast cancer contributes to the tumorigenesis. , 2015, , .		0
98	Abstract 515: Cell fate determination factor DACH1 inhibits lung adenocarcinoma invasion and tumor growth through repression of CXCL5 signaling. , 2015, , .		0
99	DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. Journal of Hematology and Oncology, 2014, 7, 73.	17.0	54
100	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. Journal of Hematology and Oncology, 2014, 7, 87.	17.0	196
101	miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. Journal of Huazhong University of Science and Technology [Medical Sciences], 2014, 34, 201-206.	1.0	36
102	In Vitro Evaluation of the Inhibitory Potential of Pharmaceutical Excipients on Human Carboxylesterase 1A and 2. PLoS ONE, 2014, 9, e93819.	2.5	18
103	Relationship Between the SER Treatment Period and Prognosis of Patients with Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6415-6419.	1.2	3
104	A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica, 2013, 126, 607-608.	7.7	9
105	Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation. International Journal of Oncology, 2013, 42, 2094-2102.	3.3	27
106	Prolonged Inhibition of Glioblastoma Xenograft Initiation and Clonogenic Growth following In Vivo Notch Blockade. Clinical Cancer Research, 2013, 19, 3224-3233.	7.0	48
107	Bis(4-methylimidazolium) succinate succinic acid solvate. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o607-o608.	0.2	2
108	Characterization of Magnetic Fluorescence Fe₃O₄/CdSe Nanocomposites. Journal of Nanoscience and Nanotechnology, 2009, 9, 1304-1307.	0.9	6

#	Article	IF	Citations
109	Astrocytes facilitate the growth and differentiation of co-cultured mesenchymal stem cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 333-336.	1.0	2
110	4,4â€²-Methylenedianilinium bis(3-carboxy-4-hydroxybenzenesulfonate) monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1947-o1948.	0.2	1
111	Bevacizumab-associated Reversible Hypotension. Clinical Oncology, 2007, 19, 800-801.	1.4	4
112	CYFRA 21-1 as an early predictor of first line chemotherapy response in advanced non small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2007, 6, P250-P253.	0.1	1
113	Fe3O4/CdSe/ZnS magnetic fluorescent bifunctional nanocomposites. Nanotechnology, 2006, 17, 2850-2854.	2.6	52
114	Mechanism ofin vitro differentiation of bone marrow stromal cells into neuron-like cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2004, 24, 259-261.	1.0	12
115	Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization. World Journal of Gastroenterology, 2004, 10, 1876.	3.3	22
116	Relationship between encephalopathy and portal vein-vena cava shunt: Value of computed tomography during arterial portography. World Journal of Gastroenterology, 2004, 10, 1939.	3.3	4